HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
Company Advances HCB101 Clinical Development, Taiwan Innovation Board Listing Process, and Global Partnering Efforts
[Taipei, Shanghai, San Francisco | May 21, 2026] – HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
Since its TPEx Emerging Stock Board registration on June 20, 2025, HanchorBio has continued to advance its capital market strategy. The Company completed a NT$680 million cash capital increase in September 2025 and submitted its application for listing on the Taiwan Innovation Board in late November 2025. The Company expects to complete the listing process by the end of May 2026, subject to applicable regulatory procedures.
During the meeting, Chairman and CEO Dr. Scott Liu thanked the Board of Directors and shareholders for their continued support. He noted that HanchorBio’s clinical and development programs are progressing steadily, and that the Company will continue to allocate resources toward assets with strong clinical differentiation and global partnering potential.
Supported by the first upfront payment from the licensing of its lead asset HCB101, HanchorBio reported 2025 revenue of NT$312 million. The Company also significantly reduced its net loss, with loss per share improving to NT$2.26, reflecting a more stable financial position.
Dr. Liu stated that 2026 marks an important transition year for HanchorBio as the Company moves from generating clinical proof-of-concept toward broader value realization across business development and capital markets. HanchorBio will prioritize core clinical assets, including HCB101, HCB301, HCB303, and HCB206, and continue to execute the “3-3-2-2+1” value matrix strategy to support clinical development, regulatory preparation, and partnering discussions.
Under this strategy, HanchorBio aims to generate Phase 2a proof-of-concept data for HCB101 across three indications in 2026, advance three programs through IND-enabling activities, support two IND applications with at least one targeting international markets, complete Phase 2a enrollment for HCB101 in second-line gastric cancer, and continue pursuing international licensing opportunities as the “+1” component of the strategy.
HanchorBio also continues to expand clinical proof-of-concept opportunities across additional indications while strengthening the differentiated position of its proprietary FBDB™ platform. The Company is aligning its business development activities closely with upcoming clinical milestones and continues to evaluate international partnering opportunities that may support future clinical development and long-term value creation.
Looking ahead, HanchorBio will remain focused on advancing breakthrough therapies in oncology and autoimmune diseases, increasing the partnering potential of its core assets, and optimizing resource allocation to support long-term shareholder value.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.